Citation: E. Felip, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC), ANN ONCOL, 12(8), 2001, pp. 1049-1050
Citation: E. Felip, ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC), ANN ONCOL, 12(8), 2001, pp. 1051-1052
Authors:
Isla, D
Rosell, R
Sanchez, JJ
Carrato, A
Felip, E
Camps, C
Artal, A
Gonzalez-Larriba, JL
Azagra, P
Alberola, J
Martin, C
Massuti, B
Citation: D. Isla et al., Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer, J CL ONCOL, 19(4), 2001, pp. 1071-1077
Citation: R. Rosell et E. Felip, Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer, SEMIN ONCOL, 28(4), 2001, pp. 37-44
Authors:
Monzo, M
Rosell, R
Felip, E
Astudillo, J
Sanchez, JJ
Maestre, J
Martin, C
Font, A
Barnadas, A
Abad, A
Citation: M. Monzo et al., A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers, J CL ONCOL, 17(7), 1999, pp. 2100-2104
Authors:
Ferrer, J
Villarino, MA
Encabo, G
Felip, E
Bermejo, B
Vila, S
Orriols, R
Citation: J. Ferrer et al., Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuronspecific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions, CANCER, 86(8), 1999, pp. 1488-1495